



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

TG 100713

Cat. No.:	HY-13514
CAS No.:	925705-73-3
Molecular Formula:	C ₁₂ H ₁₀ N ₆ O
Molecular Weight:	254.25
Target:	PI3K
Pathway:	PI3K/Akt/mTOR
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 6.41 mg/mL (25.21 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	3.9331 mL	19.6657 mL	39.3314 mL	
		5 mM	0.7866 mL	3.9331 mL	7.8663 mL	
		10 mM	0.3933 mL	1.9666 mL	3.9331 mL	
Please refer to the solubility information to select the appropriate solvent.						

BIOLOGICAL ACTIVITY

Description	TG 100713 is an inhibitor of PI3K, with IC ₅₀ s of 24, 50, 165, and 215 nM for PI3Kδ, γ, α and β isoforms respectively ^[1] .			
IC ₅₀ & Target	PI3Kδ 24 nM (IC ₅₀)	PI3Kγ 50 nM (IC ₅₀)	PI3Kα 165 nM (IC ₅₀)	PI3Kβ 215 nM (IC ₅₀)
In Vitro	TG100713 (10 μM; 48 or 72 h) strongly inhibits endothelial cell (EC) proliferation ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

CUSTOMER VALIDATION

- Sci Rep. 2022 Apr 12;12(1):6090.
- Molecules. 2020 Apr 23;25(8):1980.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Doukas J, et, al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19866-71.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA